Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Sarcoma 17Glioblastoma 10Brain Neoplasms 10Gliosarcoma 9Rhabdomyosarcoma 7Osteosarcoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Sarcoma, Ewing 5Recurrence 5Leukemia, Myeloid, Acute 5Dendritic Cell Sarcoma, Interdigitating 5Burkitt Lymphoma 5Astrocytoma 5Oligodendroglioma 4Myeloproliferative Disorders 4Myelodysplastic Syndromes 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Hodgkin Disease 4Glioma 4Rhabdoid Tumor 3Primary Myelofibrosis 3Neurofibrosarcoma 3Neuroblastoma 3

Interventions

temsirolimus 1Sorafenib 1Sirolimus 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrent Uterine Sarcoma × Sirolimus × Sarcoma × Clear all
NCT01061606 2016-11-09

Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus

National Cancer Institute (NCI)

Phase 2 Terminated
8 enrolled 6 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡